Immunocore Ltd
Clinical trials sponsored by Immunocore Ltd, explained in plain language.
-
New hope for advanced melanoma: combo therapy trial now recruiting
Disease control Recruiting nowThis study tests a new drug (brenetafusp) plus nivolumab against standard nivolumab treatments for people with a specific genetic type (HLA-A*02:01) who have advanced melanoma that hasn't been treated yet. About 680 participants will be enrolled to see if the combination helps de…
Phase: PHASE3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 17, 2026 04:10 UTC
-
New immune drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug, IMC-P115C, designed to help the immune system find and attack cancer cells that have a protein called PRAME. It is for people with advanced solid tumors who have a specific genetic marker (HLA-A*02:01) and have tried other treatments. The …
Phase: PHASE1 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug, IMC-R117C, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific protein (PIWIL1) and a certain immune type (HLA-A*02:01). The goal is to see if the drug is safe and can shrink tumors. About 600 a…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug combo aims to extend life in advanced melanoma
Disease control Recruiting nowThis study tests whether tebentafusp, alone or with pembrolizumab, helps people with advanced non-ocular melanoma live longer compared to standard treatments. It involves 540 adults whose tumors have a specific genetic marker (HLA-A*02:01) and have already tried other therapies. …
Phase: PHASE3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 11, 2026 20:51 UTC